Comparative Pharmacology

Head-to-head clinical analysis: DELFLEX W DEXTROSE 2 5 LOW MAGNESIUM IN PLASTIC CONTAINER versus DELFLEX W DEXTROSE 3 5 IN PLASTIC CONTAINER.

Peer-Reviewed Evidence

Differential Analysis

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER vs DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

DELFLEX W/ DEXTROSE 2.5% LOW MAGNESIUM IN PLASTIC CONTAINER

Peritoneal dialysis solution

Category C

DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

Peritoneal dialysis solution

Category C

Head-to-Head

Clinical Matrix

Mechanism of Action

Intraperitoneal administration of dextrose and electrolytes creates an osmotic gradient that promotes ultrafiltration and removal of uremic toxins and excess fluid across the peritoneal membrane. Low magnesium formulation reduces magnesium load in patients with hypermagnesemia or renal impairment.

Delflex with Dextrose 3.5% is a peritoneal dialysis solution that uses a high concentration of dextrose to create an osmotic gradient, drawing water and solutes from the blood across the peritoneal membrane into the dialysate, thereby removing excess fluid and waste products from the body. Dextrose is metabolized locally and systemically.

Clinical Dosing

Intraperitoneal instillation of 2 L (or as prescribed) of 2.5% dextrose-containing peritoneal dialysis solution, typically exchanged 4 times daily. The volume and frequency are individualized based on patient's size, residual renal function, and ultrafiltration needs.

Intraperitoneal administration: 2000 mL per exchange, typically 4 exchanges per day, with dwell times of 4-6 hours (CAPD) or cycler-adjusted for APD.

Direct Interaction

None Documented